The EMA Safety Committee (PRAC) has concluded that unusual blood clots with low platelets should be reported as very rare side effects of Vaxzevria (formerly COVID-19 AstraZeneca vaccine ).
The European Medicines Agency is currently holding a press conference.
The EMA reminds health professionals and people receiving the vaccine to be aware of the possibility of very rare cases of thrombosis in combination with low platelet counts within 2 weeks of vaccination.
So far, most of the reported cases have occurred in women under 60 years of age within 2 weeks of vaccination. Based on the available data, specific risk factors have not been confirmed.
What the EMA recommends to those who have been vaccinated
Those who have received the vaccine should seek medical help immediately if they experience symptoms of this combination of thrombosis and low platelets.
The reported combination of thrombosis and low platelets is very rare and the overall benefits of the vaccine in preventing COVID-19 outweigh the risks of side effects.
The committee has thoroughly investigated the 62 cases of cerebral thrombosis and 24 cases of visceral arterial thrombosis reported in the EU since 22 March, 18 of which were fatal. The cases came from a total of 25 million people who have been vaccinated in Europe and the United Kingdom.